Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07551635Phase 2Not Yet Recruiting

SMARCA4/2 Inhibitor for POU2F3-Positive SCLC

Role: collaborator

NCT07283094Phase 1Recruiting

FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

Role: collaborator

NCT04891757Phase 1Active Not Recruiting

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Role: lead

NCT04965753Phase 1Terminated

FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors

Role: lead

NCT04879017Phase 1Terminated

FHD-286 in Subjects With Metastatic Uveal Melanoma

Role: lead

All 5 trials loaded